Press Releases Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:38:18 12/05/2026 BST			5-day change	1st Jan Change
38.44 ^EUR	+3.67%		+1.42%	+3.86%

05-12	Bayer: An assuring quarter towards gradual transformation
05-12	DAX Index Blinks Red as German Inflation Accelerates	MT

Press Releases

05-12	Bayer : Q1 Media Update	PU
05-12	Bayer : First Quarter 2026 Results and Media Update	PU
05-12	Bayer : Quarterly Statement First Quarter 2026	PU
05-12	Bayer : reports solid start to the year and confirms currency-adjusted Group guidance for 2026	PU
05-07	Bayer and bp Form Strategic Alliance to Jointly Scale Camelina as Intermediate Crop for Biofuels	AQ
05-07	Bayer : China’s Center of Drug Evaluation grants Priority Review designation for Bayer’s FXIa inhibitor	PU
05-07	Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis	BU
05-06	Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline	BU
04-30	Bayer - New study highlights societal optimism toward breakthrough science, and rising anxiety about how fast the world is changing	AQ
04-29	New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing	BU
04-29	Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian	BU
04-29	Bayer : China’s Center of Drug Evaluation accepts marketing authorization application for asundexian in stroke prevention after a non-cardioembolic ischemic stroke or transient ischemic attack	PU
04-29	Bayer : New study highlights societal optimism toward breakthrough science, and rising anxiety about how fast the world is changing	PU
04-27	Bayer : Notice of Dividend 2026	PU
04-25	Bayer : Results (voting results asm 2026)	PU
04-24	Bayer : Results (voting results asm2026)	PU
04-24	Bayer : Annual Stockholders' Meeting 2026	PU
04-24	Bayer : Address by Bill Anderson	PU
04-24	Bayer : Explanations relating to the Supervisory Board Report	PU
04-24	Bayer : “We see great progress, but the work isn’t complete yet”	PU
04-23	Bayer : Privacy Information for Attendees (privacy information for attendees asm2026)	PU
04-20	Bayer : AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease	PU
04-16	Bayer : Asundexian OCEANIC-STROKE Phase III study results demonstrating substantial reduction in ischemic stroke with no increase in ISTH major bleeding versus placebo published in New England Journal of Medicine	PU
04-01	Bayer : strongest-ever pharma portfolio and promising pipeline drive future growth	PU
03-31	Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential	BU